SIVELESTAT (SELECTIVE NEUTROPHIL ELASTASE INHIBITOR) IMPROVES THE MORTALITY RATE OF SEPSIS ASSOCIATED WITH BOTH ACUTE RESPIRATORY DISTRESS SYNDROME AND DISSEMINATED INTRAVASCULAR COAGULATION PATIENTS

Neutrophil elastase plays an important role in the development of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC) in sepsis. Sivelestat is a selective neutrophil elastase inhibitor. It is possible that sivelestat improves the outcome of septic patients associated with ARDS and DIC. A retrospective data analysis of septic patients associated with ARDS and DIC was conducted to investigate the effects of sivelestat. Observational period was 5 days after admission to intensive care unit (ICU). The study included 167 septic patients associated with ARDS and DIC. Control group included 133 patients without sivelestat, and sivelestat group included 34 patients started to deadministered sivelestat on the admission to ICU. The lung injury scores and PaO2/FiO2 ratio of the sivelestat group were significantly more severe than those of the control group from days 1 to 4. On day 5, the lung injury score and PaO2/FiO2 ratio of the sivelestat group improved to the same levels of those of the control group. The DIC score of sivelestat group improved on day 3 in comparison to day 1, and those of control group remained unchanged until day 4. The length of ICU stay of the sivelestat group was significantly shorter than that of the control group. A stepwise multiple logistic-regression analysis showed the sivelestat administration to be an independent predictor of survival of the septic patients associated with both ARDS and DIC. The length of ICU stay of the sivelestat group was significantly shorter than that of the control group. In addition, sivelestat administration was found to be an independent predictor of survival of those patients.

[1]  N. Matsuda,et al.  Systemic Inflammation and Disseminated Intravascular Coagulation in Early Stage of ALI and ARDS: Role of Neutrophil and Endothelial Activation , 2004, Inflammation.

[2]  H. Cate,et al.  Pathophysiology of disseminated intravascular coagulation in sepsis. , 2000, Critical care medicine.

[3]  Edward Abraham,et al.  Neutrophils and acute lung injury , 2003, Critical care medicine.

[4]  S. Idell.  Coagulation, fibrinolysis, and fibrin deposition in acute lung injury , 2003, Critical care medicine.

[5]  M. Ogawa,et al.  Relationship between neutrophil elastase and acute lung injury in humans. , 2004, Pulmonary pharmacology & therapeutics.

[6]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[7]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[8]  N. Matsuda,et al.  Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation. , 2005, Thrombosis research.

[9]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[10]  M. Suzuki,et al.  ONO-5046, a novel inhibitor of human neutrophil elastase. , 1991, Biochemical and biophysical research communications.

[11]  Y. Kakihana,et al.  Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome , 2006, Journal of Anesthesia.

[12]  H. K. Bourns.  Management of Sepsis , 1960, The Medical journal of the South-West.

[13]  F. Kunimoto,et al.  Pilot Study of the Effects of ONO-5046 in Patients with Acute Respiratory Distress Syndrome , 2004, Anesthesia and analgesia.

[14]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[15]  G. Downey,et al.  Proteases and lung injury , 2003, Critical care medicine.

[16]  G. Bernard,et al.  Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study , 2004, Critical care medicine.

[17]  Arthur S Slutsky,et al.  Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—A review , 2006, Critical care medicine.

[18]  M. Hayakawa,et al.  The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. , 2007, Thrombosis research.

[19]  Yasuhiro Ohtomo,et al.  A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria* , 2006, Critical care medicine.

[20]  H. ten Cate.  Pathophysiology of disseminated intravascular coagulation in sepsis. , 2000, Critical care medicine.

[21]  H. Hirasawa,et al.  Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure , 2002, Critical care medicine.

[22]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[23]  O. Kemmotsu,et al.  Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis* , 2002, Critical care medicine.

[24]  N. Christou,et al.  Endothelial Cells: Role in Infection and Inflammation , 1998, World Journal of Surgery.

[25]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[26]  S. Endo,et al.  Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. , 2006, Research communications in molecular pathology and pharmacology.

[27]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[28]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.